Ras association domain family 1A: A promising prognostic marker in recurrent nonmuscle invasive bladder cancer

Clinical Genitourinary Cancer

Volumn 10, Issue 2, 2012, Pages 114-120

  Kim, Ji Sang ^a,b   Chae, Yunbyung ^c   Ha, Yun Sok ^a,d   Kim, Isaac Yi ^d   Byun, Seok Soo ^e   Yun, Seok Joong ^a   Kim, Wun Jae ^a,b  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chungbuk National University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e Seoul National University Bundang Hospital   (South Korea)

Author keywords

Bladder cancer; Methylation; Prognosis; RASSF1A

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; CISPLATIN; MITOMYCIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CHILD; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON MUSCLE INVASIVE BLADDER CANCER; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PROMOTER REGION; PROTEIN METHYLATION; RECURRENT CANCER; SCHOOL CHILD; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHILD; DNA METHYLATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84862095191     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.12.003     Document Type: Article

References (33)

1. D.S. Kaufman, W.U. Shipley, A.S. Feldman Bladder cancer Lancet 374 2009 239 249
2. Y.S. Ha, M.J. Kim, H.Y. Yoon mRNA expression of S100A8 as a prognostic marker for progression of non-muscle-invasive bladder cancer Korean J Urol 51 2010 15 20
3. M. Babjuk, W. Oosterlinck, R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder Eur Urol 54 2008 303 314
4. R.J. Sylvester, A.P. van der Meijden, W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466-5
5. W.J. Kim, S.C. Bae Molecular biomarkers in urothelial bladder cancer Cancer Sci 99 2008 646 652
6. L. Sagnak, H. Ersoy, U. Ozok Predictive value of urinary interleukin-8 cutoff point for recurrences after transurethral resection plus induction bacillus Calmette-Guérin treatment in non-muscle-invasive bladder tumors Clin Genitourin Cancer 7 2009 E16 E23
7. M.G. Bol, J.P. Baak, S. Buhr-Wildhagen Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder J Urol 169 2003 1291 1294 (Pubitemid 36323769)
8. W.M. Murphy, K. Takezawa, N.A. Maruniak Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care J Urol 168 2002 968 972
9. M.I. Lerman, J.D. Minna The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium Cancer Res 60 2000 6116 6133
10. M. Malumbres, A. Pellicer RAS pathways to cell cycle control and cell transformation Front Biosci 3 1998 d887 d912
11. M.S. Song, S.J. Song, N.G. Ayad The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex Nat Cell Biol 6 2004 129 137 (Pubitemid 38425712)
12. J.W. Catto, A.R. Azzouzi, I. Rehman Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma J Clin Oncol 23 2005 2903 2910 (Pubitemid 46224108)
13. R. Maruyama, S. Toyooka, K.O. Toyooka Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features Cancer Res 61 2001 8659 8663 (Pubitemid 34013873)
14. M.W. Chan, L.W. Chan, N.L. Tang Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients Int J Cancer 104 2003 611 616 (Pubitemid 36337261)
15. S. Jarmalaite, F. Jankevicius, K. Kurgonaite Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer Oncology 75 2008 145 151
16. H.H. Lin, H.L. Ke, S.P. Huang Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine Urol Oncol 28 2010 597 602
17. M.G. Lee, H.Y. Kim, D.S. Byun Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma Cancer Res 61 2001 6688 6692
18. V. Phé, O. Cussenot, M. Rouprêt Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract BJU Int 104 2009 896 901
19. F.L. Greene American Joint Committee on Cancer Updating the strategies in cancer staging Bull Am Coll Surg 87 2002 13 15
20. A. Stenzl, N.C. Cowan, M. De Santis The updated EAU guidelines on muscle-invasive and metastatic bladder cancer Eur Urol 55 2009 815 825
21. D.R. Yates, I. Rehman, M.F. Abbod Promoter hypermethylation identifies progression risk in bladder cancer Clin Cancer Res 13 2007 2046 2053 (Pubitemid 46649871)
22. S. Al-Sukhun, M. Hussain Molecular biology of transitional cell carcinoma Crit Rev Oncol/Hematol 47 2003 181 193 (Pubitemid 36957861)
23. W.J. Kim, E.J. Kim, S.K. Kim Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer Mol Cancer 9 2010 3
24. X.R. Wu Urothelial tumorigenesis: a tale of divergent pathways Nat Rev Cancer 5 2005 713 725
25. L.S. Borden Jr., P.E. Clark, M.C. Hall Bladder cancer Curr Opin Oncol 15 2003 227 233 (Pubitemid 36735178)
26. C.T. Lee, R.L. Dunn, C. Ingold Early-stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion Urology 69 2007 1068 1072 (Pubitemid 46891598)
27. V.A. Ramani, S.J. Bromage, N.W. Clarke A contemporary standard for morbidity and outcome after radical cystectomy BJU Int 104 2009 628 632
28. R. Hurle, A. Losa, A. Manzetti Intravesical bacille Calmette- Guérin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up Urology 54 1999 258 263 (Pubitemid 29367248)
29. S.F. Shariat, G.S. Palapattu, P.I. Karakiewicz Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy Eur Urol 51 2007 152 160 (Pubitemid 44821530)
30. S. Duarte-Pereira, F. Paiva, V.L. Costa Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma Eur J Cancer 47 2011 1106 1114
31. V. Cebrian, M. Fierro, E. Orenes-Piñero KISS1 methylation and expression as tumor stratification biomarkers and clinical outcome prognosticators for bladder cancer patients Am J Pathol 179 2011 540 546
32. T. Reinert, C. Modin, F.M. Castano Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers Clin Cancer Res 17 2011 5582 5592
33. W. Chung, J. Bondaruk, J. Jelinek Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments Cancer Epidemiol Biomarkers Prev 20 2011 1483 1491